感染病中的免疫检查点阻断。
Immune checkpoint blockade in infectious diseases.
机构信息
QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, Queensland 4006, Australia.
The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Victoria 3000, Australia.
出版信息
Nat Rev Immunol. 2018 Feb;18(2):91-104. doi: 10.1038/nri.2017.112. Epub 2017 Oct 9.
Abstract
The upregulation of immune checkpoint molecules, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4), on immune cells occurs during acute infections, such as malaria, as well as during chronic persistent viral infections, including HIV and hepatitis B virus. These pathways are important for preventing immune-driven pathology but can also limit immune-mediated clearance of the infection. The recent success of immune checkpoint blockade in cancer therapy suggests that targeting these pathways would also be effective for preventing and treating a range of infectious diseases. Here, we review our current understanding of immune checkpoint pathways in the pathogenesis of infectious diseases and discuss the potential for therapeutically targeting these pathways in this setting.
摘要
免疫细胞表面的免疫检查点分子（如程序性细胞死亡蛋白 1（PD1）和细胞毒性 T 淋巴细胞抗原 4（CTLA4））的上调发生在急性感染（如疟疾）以及慢性持续性病毒感染（包括 HIV 和乙型肝炎病毒）期间。这些途径对于防止免疫驱动的病理很重要，但也会限制感染的免疫介导清除。免疫检查点阻断在癌症治疗中的近期成功表明，针对这些途径也将有效预防和治疗一系列传染病。在这里，我们回顾了我们目前对传染病发病机制中免疫检查点途径的理解，并讨论了在这种情况下靶向这些途径的治疗潜力。
相似文献
1
Immune checkpoint blockade in infectious diseases.感染病中的免疫检查点阻断。
Nat Rev Immunol. 2018 Feb;18(2):91-104. doi: 10.1038/nri.2017.112. Epub 2017 Oct 9.
2
Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm.抗PD-1/PD-L1疗法用于传染病：借鉴癌症治疗模式
Int J Infect Dis. 2017 Mar;56:221-228. doi: 10.1016/j.ijid.2017.01.028. Epub 2017 Feb 2.
3
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.癌症的免疫检查点阻断疗法：FDA 批准的免疫检查点抑制剂概述。
Int Immunopharmacol. 2018 Sep;62:29-39. doi: 10.1016/j.intimp.2018.06.001. Epub 2018 Jul 2.
4
T cell checkpoint regulators in the heart.心脏中的 T 细胞检查点调节剂。
Cardiovasc Res. 2019 Apr 15;115(5):869-877. doi: 10.1093/cvr/cvz025.
5
A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.在检查点阻断免疫治疗时代的 T 细胞激活的阈值模型。
Front Immunol. 2019 Mar 18;10:491. doi: 10.3389/fimmu.2019.00491. eCollection 2019.
6
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.针对免疫检查点分子的抗体恢复了肝癌浸润 T 细胞的功能。
Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.
7
Immunological and clinical implications of immune checkpoint blockade in human cancer.免疫检查点阻断在人类癌症中的免疫和临床意义。
Arch Pharm Res. 2019 Jul;42(7):567-581. doi: 10.1007/s12272-019-01140-1. Epub 2019 Mar 6.
8
Recent advances in the clinical development of immune checkpoint blockade therapy.免疫检查点阻断疗法的临床开发进展。
Cell Oncol (Dordr). 2019 Oct;42(5):609-626. doi: 10.1007/s13402-019-00456-w. Epub 2019 Jun 14.
9
Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.社论：免疫检查点分子与癌症免疫疗法
Front Immunol. 2018 Dec 5;9:2878. doi: 10.3389/fimmu.2018.02878. eCollection 2018.
10
Combination cancer immunotherapy and new immunomodulatory targets.联合癌症免疫疗法和新的免疫调节靶点。
Nat Rev Drug Discov. 2015 Aug;14(8):561-84. doi: 10.1038/nrd4591.
引用本文的文献
1
Genomic insights on lung cancer risk: identifying new variants in Amazonian indigenous populations.肺癌风险的基因组学见解：在亚马逊原住民群体中识别新的变异
Clin Transl Oncol. 2025 Aug 28. doi: 10.1007/s12094-025-04033-6.
2
Host Immune Response in Chronic Hepatitis Delta: Implications for Pathogenesis and Therapy.慢性丁型肝炎中的宿主免疫反应：对发病机制和治疗的影响
Pathogens. 2025 Aug 21;14(8):828. doi: 10.3390/pathogens14080828.
3
Modulates the Expansion of Terminally Exhausted CD4 and CD8 T-Cells in Individuals with HIV-TB Co-Infection.调节HIV-TB合并感染个体中终末耗竭的CD4和CD8 T细胞的扩增。
Pathogens. 2025 Aug 11;14(8):802. doi: 10.3390/pathogens14080802.
4
Safety of immune checkpoint inhibitors in cancer patients with COVID-19: A review.免疫检查点抑制剂在新冠肺炎癌症患者中的安全性：综述
Medicine (Baltimore). 2025 Aug 8;104(32):e43579. doi: 10.1097/MD.0000000000043579.
5
Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies.基于片段的免疫细胞衔接抗体在癌症、感染性疾病和自身免疫性疾病治疗中的应用：临床和转化研究的经验与见解
Antibodies (Basel). 2025 Jun 24;14(3):52. doi: 10.3390/antib14030052.
6
The role of gut microbial metabolites in the T cell lifecycle.肠道微生物代谢产物在T细胞生命周期中的作用。
Nat Immunol. 2025 Jul 21. doi: 10.1038/s41590-025-02227-2.
7
Case Report: Immune checkpoint inhibitor exhibits dual benefits for a refractory lymphoma patient with disseminated mucormycosis.病例报告：免疫检查点抑制剂对一名患有播散性毛霉菌病的难治性淋巴瘤患者显示出双重益处。
Front Med (Lausanne). 2025 Jul 2;12:1608828. doi: 10.3389/fmed.2025.1608828. eCollection 2025.
8
Rapid Initiation of Antiretroviral Therapy Suppresses T Cell Pathological Proliferation and Improves Immune Recovery in People Living with HIV.快速启动抗逆转录病毒疗法可抑制HIV感染者的T细胞病理性增殖并改善免疫恢复。
Infect Drug Resist. 2025 Jul 9;18:3427-3437. doi: 10.2147/IDR.S522910. eCollection 2025.
9
A novel, rapid, and practical prognostic model for sepsis patients based on dysregulated immune cell lactylation.一种基于免疫细胞乳酸化失调的新型、快速且实用的脓毒症患者预后模型。
Front Immunol. 2025 Jun 19;16:1625311. doi: 10.3389/fimmu.2025.1625311. eCollection 2025.
10
Immunopathological features of highly pathogenic Korean Lineage B PRRSV-2: insights into virulence indicators and host immune responses.高致病性韩国谱系B型猪繁殖与呼吸综合征病毒2的免疫病理学特征：对毒力指标和宿主免疫反应的见解
Front Immunol. 2025 Jun 18;16:1599468. doi: 10.3389/fimmu.2025.1599468. eCollection 2025.
本文引用的文献
1
Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy.接受抑制性抗逆转录病毒治疗的人类免疫缺陷病毒感染个体血液、直肠和淋巴结组织中的人类免疫缺陷病毒持续性及T细胞活化
J Infect Dis. 2017 Mar 15;215(6):911-919. doi: 10.1093/infdis/jix039.
2
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.肺癌患者接受PD-1靶向治疗后外周血中PD-1+ CD8 T细胞的增殖情况。
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998. doi: 10.1073/pnas.1705327114. Epub 2017 Apr 26.
3
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.抗PD-L1抗体BMS-936559在接受抗逆转录病毒抑制治疗的HIV-1感染参与者中的临床试验。
J Infect Dis. 2017 Jun 1;215(11):1725-1733. doi: 10.1093/infdis/jix191.
4
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.T细胞活力与肿瘤负荷之比与抗PD-1反应相关。
Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.
5
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.VISTA是一种抑制性免疫检查点，在前列腺癌患者接受伊匹单抗治疗后会升高。
Nat Med. 2017 May;23(5):551-555. doi: 10.1038/nm.4308. Epub 2017 Mar 27.
6
Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8 T Cell Exhaustion Marker Expression.早期和延迟抗逆转录病毒疗法导致CD8 T细胞耗竭标志物表达的降低程度相当。
AIDS Res Hum Retroviruses. 2017 Jul;33(7):658-667. doi: 10.1089/AID.2016.0324. Epub 2017 Apr 25.
7
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.通过靶向PD-1疗法挽救耗竭的CD8 T细胞是依赖CD28的。
Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9.
8
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.TIGIT和CD96：癌症免疫治疗的新型检查点受体靶点
Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518.
9
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B.靶向线粒体功能障碍可恢复慢性乙型肝炎中耗竭的 HBV 特异性 CD8 T 细胞的抗病毒活性。
Nat Med. 2017 Mar;23(3):327-336. doi: 10.1038/nm.4275. Epub 2017 Feb 6.
10
Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection.慢性 SIV 感染期间 SIV 特异性 CXCR5+ CD8 T 细胞的动力学。
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1976-1981. doi: 10.1073/pnas.1621418114. Epub 2017 Feb 3.
Zotero 插件